• CCK-8 Suppresses IgG1 in LPS-Activated B Cells

  2026-09-14

  The 2011 reference study showed that sulfated CCK-8 suppresses proliferation, IgG1 mRNA expression, and IgG1 production in LPS-activated mouse B cells, with the principal effect attributed to CCK2R signaling. Its mechanistic contribution was to connect this humoral immune effect with time-dependent regulation of Blimp1, Pax5, Xbp1, and Bcl6, providing a framework for studying CCK-mediated immune deactivation.

• BML-277: Chk2 Inhibition in Genome Stability

  2026-09-14

  BML-277 is a potent, selective Chk2 inhibitor for dissecting DNA damage signaling. This article translates nuclear cGAS–Chk2–TRIM41 findings into practical assay strategies while clarifying implications for T-cell radioprotection and cancer research.

• JNK-IN-7: Mapping Pathogen-Driven Apoptosis

  2026-09-13

  JNK-IN-7 is a selective JNK inhibitor for resolving how pathogen morphology, innate immune signaling, and apoptotic commitment intersect. This article translates Candida krusei findings into a rigorous assay strategy while defining the compound’s mechanistic scope, controls, and handling requirements.

• H. pylori–HNF4A Methylation Drives Gastric Cancer

  2026-09-12

  The 2025 reference study identifies H. pylori-induced promoter hypermethylation of HNF4A as a mechanistic link between infection, loss of gastric epithelial polarity, TGFβ-associated EMT signaling, and gastric cancer progression. Its integrated clinical, single-cell, methylation, perturbation, and rescue experiments provide a framework for testing infection-associated epigenetic silencing in gastric cancer models.

• Preserving Phosphosignals in Liver Regeneration

  2026-09-11

  A mechanistic and translational perspective on how phosphatase control strengthens studies of SPP2, BMP signaling, liver regeneration, and phosphoproteomic analysis. The article positions Phosphatase Inhibitor Cocktail 1 (100X in DMSO) as a sample-integrity tool rather than a substitute for biological validation.

• Adenosine Triphosphate (ATP) in Metabolic Assays

  2026-09-11

  Learn how to use ATP as both an experimental reagent and an energy-state readout in workflows studying OGDH, mitochondrial proteostasis, and purinergic signaling. This guide pairs practical ATP handling with assay designs that distinguish altered metabolism from extracellular receptor effects.

• Halazone and Sodium Current Inactivation in Frog Nerves

  2026-09-10

  The Rack, Rubly, and Waschow study used voltage-clamped frog myelinated nerve fibers to compare Halazone with oxidants and residue-selective reagents. Its central finding was that Halazone strongly disrupts sodium-current inactivation, while the reagent comparison weakens a simple methionine-centered mechanism and supports a tentative role for membrane-lipid modification.

• Recombinant Human FGF-19: Assay Reliability Guide

  2026-09-10

  A scenario-driven guide to using Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050, in proliferation, viability, receptor-binding, and cytotoxicity workflows. It connects validated product specifications with practical controls, reconstitution guidance, and limitations relevant to metabolic and renal-injury research.

• ARCA for Translational mRNA Reprogramming

  2026-09-09

  A mechanistic and strategic guide to using Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, to improve synthetic mRNA performance in reprogramming, gene editing, and mRNA therapeutics research while keeping product-specific evidence distinct from broader workflow considerations.

• Aprotinin: Workflows for Protease-Sensitive Assays

  2026-09-09

  Aprotinin helps researchers control serine protease activity in fibrinolysis, inflammation, cell, and red blood cell membrane workflows. This guide combines practical titration, sample-handling safeguards, and a mechanics-focused interpretation of the RBC membrane reference study.

• SU5416: From VEGFR2 Blockade to Vascular Systems Biology

  2026-09-08

  SU5416 (Semaxanib) is more than a conventional angiogenesis tool: it offers a receptor-level perturbation for studying VEGFR2 signaling while opening a translational framework that connects endothelial biology, HIF1α-driven vascular remodeling, and immune regulation.

• Phebestin and Aminopeptidase Targeting in Malaria

  2026-09-08

  The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar antiplasmodial compound active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. By combining stage-specific assays, washout experiments, computational binding analysis, and rodent models, the work connects parasite suppression with possible PfM1AAP and PfM17LAP targeting while defining important limitations for further development.

• Ginsenoside Rg1: From Neuroimmune Signal to Strategy

  2026-09-07

  A translational perspective on how Ginsenoside Rg1 connects Treg-dependent gut–immune–brain restoration with more rigorous neuroprotection research, while defining the experimental controls, product-quality considerations, and boundaries required for credible advancement.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-07

  Pladevall-Morera et al. showed that high-grade glioma cells lacking ATRX are more vulnerable to selected multi-targeted receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient cells. The study also identified enhanced toxicity when these inhibitors were combined with temozolomide, supporting ATRX status as a useful stratification variable for translational glioma research and clinical-trial interpretation.

• Honokiol in CD8+ T Cell Metabolism Research

  2026-09-05

  Use Honokiol as a controlled chemical perturbation to connect NF-κB, oxidative stress, inflammation, and CD8+ T-cell metabolic assays. This workflow translates the CD28-ARS2-PKM findings into testable experiments while clearly separating established evidence from hypothesis-generating applications.

8734 records 1/583 page Next 12345 下5页 Last page